Penumbra, Inc. (PEN) is a publicly traded Healthcare sector company. As of May 21, 2026, PEN trades at $327.39 with a market cap of $12.84B and a P/E ratio of 74.72. PEN moved +0.24% today. Year to date, PEN is +3.93%; over the trailing twelve months it is +16.45%. Its 52-week range spans $186.97 to $362.41. Analyst consensus is neutral with an average price target of $353.00. Rallies surfaces PEN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Who is trading PEN stock inside the company?
Recent PEN insider activity includes Grewal Harpreet sold 100, Yuen Maggie sold 2.43K, Grewal Harpreet sold 186, Wilder Thomas sold 186, and Bose Arani sold 2.03K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
PEN Key Metrics
Key financial metrics for PEN
Metric
Value
Price
$327.39
Market Cap
$12.84B
P/E Ratio
74.72
EPS
$4.38
Dividend Yield
0.00%
52-Week High
$362.41
52-Week Low
$186.97
Volume
367.59K
Avg Volume
0
Revenue (TTM)
$1.45B
Net Income
$171.05M
Gross Margin
67.39%
Recent PEN Insider Trades
Grewal Harpreet sold 100 (~$32.82K) on Apr 2, 2026.
Yuen Maggie sold 2.43K (~$832.47K) on Mar 2, 2026.
Grewal Harpreet sold 186 (~$58.15K) on Jan 6, 2026.
Wilder Thomas sold 186 (~$57.79K) on Jan 2, 2026.
Bose Arani sold 2.03K (~$619.54K) on Dec 11, 2025.
Recent PEN insider activity includes Grewal Harpreet sold 100, Yuen Maggie sold 2.43K, Grewal Harpreet sold 186, Wilder Thomas sold 186, and Bose Arani sold 2.03K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for PEN?
Yes. Rallies tracks PEN insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is PEN research on Rallies investment advice?
No. Rallies provides research, data, and educational context for PEN. It does not provide personalized investment advice.
